Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

IVIG versus anti-D in pediatric ITP

Lioger B et al. J Pediatr. 2019; 204:225-33.

Key clinical point: In pediatric immune thrombocytopenia (ITP), treatment with intravenous immunoglobulins (IVIG) can raise platelet count rapidly.

Major finding: Treatment with IVIG was 15% more likely than anti-D immunoglobulin to raise platelet counts higher than 20 × 109/L within 24-72 hours.

Study details: A systematic review and meta-analysis of 11 studies comparing the efficacy of IVIG with that of anti-D in 704 children with ITP.

Disclosures: The meta-analysis did not have outside funding. The investigators reported financial relationships with Amgen, Novartis, Roche Pharma, Sanofi, and others.

Read the Article.


Lioger B et al. J Pediatr. 2019; 204:225-33.